Oruka Therapeutics’ (ORKA) Buy Rating Reiterated at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report sent to investors on Tuesday morning,Benzinga reports. Guggenheim currently has a $200.00 price objective on the stock.

A number of other analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Leerink Partners set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, April 30th. BTIG Research restated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday. Finally, UBS Group increased their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.30.

Oruka Therapeutics Trading Up 0.7%

Shares of NASDAQ ORKA opened at $108.12 on Tuesday. Oruka Therapeutics has a 12-month low of $14.08 and a 12-month high of $109.42. The firm has a market capitalization of $7.16 billion, a price-to-earnings ratio of -53.26 and a beta of -0.34. The firm has a 50 day moving average of $86.50 and a 200 day moving average of $62.27.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Sell-side analysts predict that Oruka Therapeutics will post -2.27 EPS for the current year.

Insider Transactions at Oruka Therapeutics

In other news, SVP Arjun Agarwal sold 9,999 shares of the stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $84.63, for a total transaction of $846,215.37. Following the completion of the transaction, the senior vice president directly owned 15,312 shares in the company, valued at approximately $1,295,854.56. This represents a 39.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. This trade represents a 0.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 181,406 shares of company stock worth $11,586,733. 23.49% of the stock is owned by insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors have recently bought and sold shares of ORKA. Algert Global LLC grew its stake in shares of Oruka Therapeutics by 3.5% in the 2nd quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after buying an additional 180 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares during the last quarter. Kennedy Capital Management LLC grew its position in Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after acquiring an additional 420 shares in the last quarter. AlphaCentric Advisors LLC grew its position in Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after acquiring an additional 626 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after acquiring an additional 788 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.